Immunologic Cross-Reactivity Between Human Neural, Neuroendocrine, and T-Lympho-Cyte Antigen

Adelman, Lester S.; Wolfe, Hubert J.; Delellis, R. A.; Mobtaker, H.; Tischler, Arthur S.

doi:10.1097/00005072-198505000-00037

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, anti-CD57 antibodies have been shown to bind specifically to myelin-associated glycoprotein [19] and to tumours arising from tissues containing myelin associated glycoprotein [2,5,15,[28][29][30]. Additional studies have demonstrated CD57 expression in thyroid tumours [6,10,16,23] and other carcinomas [4,8,12,18,21,27,32], but only rarely in normal epithelial tissues and benign lesions, such as hyperplastic prostatic epithelium [27,32].…”

Section: Introductionmentioning

confidence: 99%

CD57 (leu-7) Expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma

Khan¹,

Baker

Patwardhan

et al. 1998

Virchows Archiv

View full text Add to dashboard Cite

CD57 (HNK-1) is a oligosaccharide antigen that is expressed by cells of several lineages. It is present on multipotential neuroepithelial cells during embryogenesis, and tumours of epithelial, neuroectodermal and nerve sheath origin also express CD57. Its role in the diagnosis of thyroid tumours is controversial. We have studied CD57 expression by immunohistochemistry to determine its utility in the classification of thyroid follicular lesions. Study material included 114 normal thyroid sections, 77 benign thyroid lesions (29 colloid nodules, 22 follicular adenomas, 20 cases of Hashimoto's thyroiditis and 6 of Grave's disease) and 83 thyroid carcinomas, including 31 follicular variants of papillary carcinoma. We observed CD57 positivity in 95% of thyroid carcinomas, 27% of follicular adenomas and 10% of colloid nodules. It was not expressed in the normal thyroid. CD57 expression in thyroid carcinomas was significantly different from that in normal and benign thyroid lesions (P < 0.0001). The follicular variant of papillary thyroid carcinoma also showed significantly higher CD57 expression than colloid nodules (P < 0.0009) or follicular adenomas (P < 0.0009). No significant difference was seen between colloid nodules and follicular adenomas. We conclude that CD57 immunohistochemistry is valuable in the classification of thyroid follicular lesions into benign and malignant groups and is also helpful in the diagnosis of the follicular variant of papillary thyroid carcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

CD57 (leu-7) Expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma

Khan¹,

Baker

Patwardhan

et al. 1998

Virchows Archiv

View full text Add to dashboard Cite

show abstract

Cross-reactivity of monoclonal antibody Leu-19 with some neuroectodermal and other non-immune tissues

et al. 1990

View full text Add to dashboard Cite

Leu-19 antigen is a 200-220 kDa surface glycoprotein, initially detected on natural killer (NK) cells exhibiting non-major histocompatibility complex-restricted cytotoxicity. Using a monoclonal antibody (mAb) directed against the Leu-19 molecule, we were unable to identify NK cells immunohistologically in cryostat sections of neuroectodermal tumors. Instead, mAb Leu-19 cross-reacted with the surfaces of the tumor cells, except for melanomas. It stained mesodermal tumor cells less intensely and did not stain those of carcinoma metastases. In three plasmacytomas, cells were observed, most likely NK cells, which extend Leu-19-positive cell processes towards to the unstained tumor cells. Furthermore, the Leu-19 antigen was identified on physiological tissues, especially on all neuroendocrine cells analyzed. The cross-reactions observed with Leu-19 mAb were confirmed using mAb NKH-1, which is also directed against the Leu-19 molecule. Thus, the expression of Leu-19 on neuroectodermal cells is another example of antigen sharing between specialized immune cells and the nervous system.

show abstract

Immunohistochemical recognition of human neuroepithelial tumors by anti-Leu 7 (HNK-1) monoclonal antibody

Perentes

Rubinstein

1986

Acta Neuropathol

View full text Add to dashboard Cite

The immunoreactivity of the anti-Leu 7 (HNK-1) monoclonal antibody, a marker for natural killer cells, was evaluated with the peroxidase-anti-peroxidase (PAP) method on sections of human paraffin-embedded tissues from 135 tumors of the central nervous system and five esthesioneuroblastomas. As shown independently by others, the antibody was found to react with most types of neoplastic neuroepithelial cells. Our findings indicate that the reaction is most often localized on the cytoplasmic membranes. The immunoreactive cell membranes were generally those of well-differentiated tumor cells and of neoplastic cells found in tumors that usually were not embryonal in nature. Parallel immunostaining either of the same or of successive sections with an anti-glial fibrillary acidic protein serum was of considerable assistance in discriminating between different immunoreactive cells, e.g., between astrocytes and cells presumed to be oligodendrocytes. Despite its cross-recognition of cells of various histogenesis, the anti-Leu 7 monoclonal antibody can, in well-defined circumstances, elucidate specific differential diagnostic problems involving neurogenic neoplasms that cannot be resolved with routine staining techniques.

show abstract

Immunologic Cross-Reactivity Between Human Neural, Neuroendocrine, and T-Lympho-Cyte Antigen

Cited by 4 publications

References 0 publications

CD57 (leu-7) Expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma

CD57 (leu-7) Expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma

Cross-reactivity of monoclonal antibody Leu-19 with some neuroectodermal and other non-immune tissues

Immunohistochemical recognition of human neuroepithelial tumors by anti-Leu 7 (HNK-1) monoclonal antibody

Contact Info

Product

Resources

About